{
  "conversation_id": "42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9",
  "chat_history": "{\n  \"messages\": [\n    {\n      \"metadata\": {},\n      \"content_type\": \"message\",\n      \"role\": \"user\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Generate a comprehensive diagnostic summary for Patient ID: patient_4 including biomarker status, stage at diagnosis, treatment history, and latest imaging findings. Export the report as a formatted Word document for tumor board presentation.\"\n        }\n      ]\n    },\n    {\n      \"ai_model_id\": \"gpt-5-mini\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-CBdiQTvRTs7ssi228dBKEBZvx1wkN\",\n        \"created\": 1756890310,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 1258,\n          \"completion_tokens\": 1170\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"Orchestrator\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Checklist \u2014 planned moderation steps\\n- Validate and retrieve the requested patient timeline and history from PatientHistory.\\n- Generate current patient status from PatientStatus using that timeline.\\n- Collect imaging and radiology details and then create a tumor-board formatted Word report via ReportCreation.\\n- Provide milestone micro-updates after each agent response and ensure all agents yield back to me.\\n\\nPlanned sequence and purpose\\n1. PatientHistory \u2014 validate the patient ID and return the structured patient timeline and concise history summary (this is required first).\\n2. PatientStatus \u2014 use PatientHistory output to produce current status (age, stage at diagnosis, primary site, histology, biomarkers, treatment history, ECOG).\\n3. Radiology \u2014 summarize latest imaging findings (from PatientHistory data / reports). If images are available later, Radiology can analyze them, but for now we will rely on report text.\\n4. ReportCreation \u2014 assemble a formatted Word document for tumor board presentation using the timeline, status, radiology, pathology and treatment details.\\n5. (Optional) ClinicalTrials / MedicalResearch \u2014 if you want available clinical trials or research context, we can add them afterward.\\n\\nSpecial rule to be followed in this session\\n- Each agent, after completing their task, must yield the chat back to me (the Orchestrator) and conclude with: \\\"back to you: Orchestrator\\\"\\n\\nUser, quick confirmations before I proceed\\n- User, do you have any specific tumor-board template preferences or sections that must be emphasized in the Word document (e.g., concise one-page summary, full timeline, imaging snapshots, consent status)?\\n- Are there any privacy or PHI constraints I should be aware of before producing the Word document?\\n\\nNow I will begin by engaging the PatientHistory agent.\\n\\nPatientHistory, please proceed:\\n- Validate that the provided patient ID \\\"patient_4\\\" is a non-empty string.\\n- Retrieve and return the patient's structured timeline and concise history summary following your required JSON schema. For a successful response, include:\\n  - status: \\\"success\\\"\\n  - patient_id: \\\"patient_4\\\"\\n  - patient_timeline: an array of events (date, event_type, brief_note) reflecting diagnosis, biomarkers, staging, treatments, imaging, pathology, etc.\\n  - history_summary: concise summary (2\u20134 sentences)\\n  - error_message: null\\n- If there is an issue with the ID, return status: \\\"error\\\" and an informative error_message.\\n- After your response, conclude with: back to you: Orchestrator\\n\\nOrchestrator awaiting PatientHistory\u2019s response.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    },\n    {\n      \"ai_model_id\": \"gpt-5-mini\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-CBdmd3FUuKyUZfw4Zn1WTYWlWxXpW\",\n        \"created\": 1756890571,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 22257,\n          \"completion_tokens\": 7058\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"PatientHistory\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Here is the complete patient data organized chronologically for clear understanding. This includes all relevant information for a tumor board review:\\n- 2019-12: Initial presentation and diagnostic imaging\\n    - Patient presented in December 2019 with chest heaviness/chest pain. Initial CT in January 2020 showed a lingular pulmonary opacity suspicious for malignancy with additional bilateral pulmonary nodules and mediastinal/left hilar adenopathy. PET/CT was performed in March 2020 demonstrating a hypermetabolic lingular mass and multiple hypermetabolic mediastinal nodes; plan for bronchoscopic sampling and further workup.\\n    - Source: [Referral received for medical oncology for new diagnosis of left lung cancer. Initial workup started in December 2019 with a diagnosis of pneumonia and a need\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/0/source/0.html)\\n    - Source: [Patient with non-small cell lung cancer, likely stage IV adenocarcinoma. The plan is to start the patient on systemic chemotherapy with carboplatin and\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/0/source/1.html)\\n- 2020-03-30: Bronchoscopy with EBUS-guided FNA \u2014 pathologic diagnosis\\n    - EBUS-guided fine needle aspiration of mediastinal nodes and transbronchial sampling of the left lingula confirmed metastatic non-small cell carcinoma, favor adenocarcinoma (multiple nodal stations positive).\\n    - Source: [2020-03-30: Bronchoscopy with EBUS-guided FNA. Pathology diagnosis/interpretation: A. Lymph node, 7, EBUS guided fine needle aspiration -- metastatic non-small\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/1/source/0.html)\\n    - Source: [Patient here for chemotherapy education prior to first chemotherapy treatment with taxol + carboplatin. Patient underwent a bronchoscopy with endobronchial\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/1/source/1.html)\\n- 2020-04-30: Treatment plan: start systemic chemotherapy (carboplatin + paclitaxel)\\n    - Chemotherapy education completed and plan made to begin carboplatin + paclitaxel systemic chemotherapy (7-day cycle described) with subsequent addition of pembrolizumab per treating team if appropriate.\\n    - Source: [Patient here for education prior to first chemotherapy treatment with taxol + carboplatin. The plan is to start the patient on systemic chemotherapy with\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/2/source/0.html)\\n- 2020-06-10: First documented combined therapy administration (carboplatin + paclitaxel +/- pembrolizumab)\\n    - Chemotherapy and antiemetic premedications administered. Notes document carboplatin 550 mg and paclitaxel 300 mg given; pembrolizumab (Keytruda) was also administered that day as part of the regimen.\\n    - Source: [Patient here for Cycle 1, Day 1 chemotherapy with the addition of Keytruda. 2020-06-10: Carboplatin (Paraplatin) 550 mg ... Paclitaxel (Taxol) 300 mg ...\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/3/source/0.html)\\n- 2020-08-03 to 2020-08-10: Restaging PET/CT: partial response; molecular testing result (NGS)\\n    - Restaging PET/CT shows overall partial response with decreased size and metabolic activity of primary lingular lesion and mediastinal/hilar nodes. Next-generation sequencing (NGS) result returned showing KRAS p.G12C mutation; PD-L1 negative (reported in clinic notes).\\n    - Source: [Findings are consistent with a partial response to treatment with overall improving PET-CT when compared to the prior study. Decreasing size and metabolic\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/4/source/0.html)\\n    - Source: [2020-08-10 NGS returned showing KRAS p.G12C mutation. PD-L1 neg.](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/4/source/1.html)\\n- 2020-08-11: New severe hypothyroidism detected \u2014 levothyroxine started\\n    - TSH was very high (reported 159); provider recommended starting levothyroxine 25 mcg daily with standing orders to recheck TSH the next day and weekly CBC/CMP monitoring.\\n    - Source: [Patients tsh resulted very high at 159. Dr. Miller would like her to start levothyroxine 25 mcg daily. We will recheck tsh tomorrow when patient has treatment.\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/5/source/0.html)\\n- 2020-09-24: Completed 6 cycles carboplatin/paclitaxel + pembrolizumab\\n    - Cycle 6 of combined chemotherapy/immunotherapy completed on 2020-09-24 without incident per infusion record.\\n    - Source: [Cycle #6, Day 1 ... 2020-09-24: Pembrolizumab (Keytruda) 200 mg ... Paclitaxel (Taxol) 300 mg ... Carboplatin (Paraplatin) 550 mg ... Patient here for Cycle 6,\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/6/source/0.html)\\n- 2020-12-10 to 2020-12-28: Recommendation for maintenance pembrolizumab; first documented maintenance dose\\n    - After initial response, maintenance pembrolizumab was recommended (decision dated 2020-12-10). Documentation shows pembrolizumab 200 mg given as maintenance on 2020-12-28 (Cycle 1 Day 1 of maintenance recorded).\\n    - Source: [2020-12-10: Patient recently met with Dr. and was recommended maintenance pembrolizumab and he recommended against consolidative radiation. Recommended re-\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/7/source/0.html)\\n    - Source: [Patient here for Cycle 1, Day 1 of Keytruda treatment. Medication Administration: Pembrolizumab (Keytruda) 200 mg ... Time: 2020-12-28 1406 CST ... Treatment\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/7/source/1.html)\\n- 2021-02-15: CT chest (compare to prior) \u2014 interval growth of lingular mass\\n    - CT chest without contrast measured the lingular mass at 3.6 x 2.5 cm (previously 2.7 x 2.4 cm). Left hilar lymphadenopathy somewhat improved; a left lower lobe nodule increased to 10 x 4 mm from 7 x 6 mm. No new nodules identified. These changes were concerning for slow progression.\\n    - Source: [The lingular mass is now measured at 3.6 x 2.5 cm on image 92 of series 2. This was previously measured at 2.7 x 2.4 cm. Left hilar lymphadenopathy appears\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/8/source/0.html)\\n    - Source: [2021-02-15 CT chest without contrast impression: 1. Lingular mass now measured at 3.6 x 2.5 cm as opposed to 2.7 x 2.4 cm previously.](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/8/source/1.html)\\n- 2021-03-01 to 2021-03-11: Thyroid management and dysphagia workup (EGD with dilation and biopsies)\\n    - Levothyroxine dose adjustments for fluctuating TSH: TSH low at 0.041 on 2021-03-01, levothyroxine decreased to 75 mcg daily. Patient reported dysphagia; EGD performed 2021-03-11 showed a tight Schatzki-type ring at the gastroesophageal junction treated with balloon dilation to 15 mm. Gastric and duodenal biopsies were negative (no H. pylori, normal mucosa).\\n    - Source: [2021-03-01: TSH low at 0.041, free T4 WNL at 1.54. Decreased levothyroxine dose to 75 mcg. Patient c/o dysphagia. EGD on 2021-03-11 showed a tight stricture\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/9/source/0.html)\\n    - Source: [The gastroesophageal junction was noted to be at approximately 36 cm from the incisors. The z line appeared regular, but there was a tight stricture with\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/9/source/1.html)\\n    - Source: [Final diagnosis: a) duodenum, biopsy: 1. Normal duodenal mucosa 2. Negative for celiac disease and other enteropathy b) stomach, antrum, biopsy: 1. Normal\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/9/source/2.html)\\n- 2021-03-22: Restaging PET/CT \u2014 metabolic progression; change in systemic plan (KRAS-directed therapy considered)\\n    - PET/CT on 2021-03-22 demonstrated a new/increased intensely FDG-avid 4.1 cm left lung mass and new/increased FDG-avid left hilar and infrahilar lymphadenopathy consistent with progression. Given progression on pembrolizumab, the team planned to discontinue pembrolizumab and consider KRAS-directed therapy with adagrasib; second opinion and referral for KRAS-directed treatment arranged.\\n    - Source: [2021-03-22: Keytruda administered. PET/CT impression: 1. Increased intensely FDG avid 4.1 cm left lung mass, likely increased metabolically active\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/10/source/0.html)\\n    - Source: [Patient due for treatment on 2021-03-21 with Keytruda, but rescheduled to 2021-03-22 after the PET scan. Disease appears to be slowly progressing. Will assess\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/10/source/1.html)\\n- 2021-03-27: Follow-up visit and logistic planning\\n    - Follow-up visit for NSCLC management documenting prior history, KRAS p.G12C and PD-L1 negative status, and plans for potential transition to KRAS-directed therapy (adagrasib) following PET/CT progression. Labs and follow-up appointments scheduled (lab on 2021-04-10, clinic follow-up 2021-04-11 with treatment following).\\n    - Source: [Heme|Onc progress note date of service: 2021-03-27 ... Reason for visit: Follow-up for non-small cell lung cancer T4N3M1a (IVA). Completed treatment with\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/11/source/0.html)\\n    - Source: [Lab appointment in - 2021-04-10 at 8:31am. Follow up with dr. Miller is scheduled for 2021-04-11 at 11:01am. -treatment will be right after at 11:31am upstairs.](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/11/source/1.html)\\n- 2021-03-27 (Summary): Patient demographics and current status (summary)\\n    - 59-year-old female with stage IVA (T4 N3 M1a) metastatic lung adenocarcinoma harboring KRAS p.G12C and PD-L1 negative. Received induction carboplatin + paclitaxel + pembrolizumab (6 cycles completed 2020-09-24) followed by maintenance pembrolizumab beginning December 2020. Initial partial response on PET in 2020, later interval growth on CT (Feb 2021) and metabolic progression on PET/CT (Mar 2021). Plan: discontinue pembrolizumab and consider KRAS-directed therapy (adagrasib) with multi-disciplinary second opinion; thyroid dysfunction managed with levothyroxine (dose adjusted to 75 mcg by 2021-03-01). Dysphagia managed with EGD and dilation (2021-03-11). Cardiac calcified disease noted on imaging with PET/CT MPI/stress testing planned (2021-04-27).\\n    - Source: [Heme|Onc progress note date of service: 2021-03-20 ... Patient name: Jane M. Doe Age: 59 y.o. Oncologic history: 2020-03-07 PET/CT demonstrated hypermetabolic\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/12/source/0.html)\\n    - Source: [HPI: Jane M. Doe is a 59 y.o. female here for follow-up of her NSCLC prior to treatment with Keytruda q21-days. Oncologic history: 2020-03-07 PET/CT showed\u2026](https://app-hao-lmat-evx.azurewebsites.net/view/42b4335c914b50509e2a9c24f1fb2fae79008659a0dd713eacd1996e75c45bc9/patient_4/patient_timeline/entry/12/source/1.html)\\n\\n{\\n  \\\"status\\\": \\\"success\\\",\\n  \\\"patient_id\\\": \\\"patient_4\\\",\\n  \\\"patient_timeline\\\": [\\n    {\\n      \\\"date\\\": \\\"2019-12\\\",\\n      \\\"event_type\\\": \\\"Presentation/Imaging\\\",\\n      \\\"brief_note\\\": \\\"Initial presentation with chest heaviness; CT Jan 2020 showed lingular opacity with bilateral nodules and mediastinal/left hilar adenopathy; PET/CT planned and performed March 2020.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-03-07\\\",\\n      \\\"event_type\\\": \\\"Imaging\\\",\\n      \\\"brief_note\\\": \\\"Baseline PET/CT: hypermetabolic lingular mass (~3.4 x 3.8 cm, SUV 18.4), multiple mediastinal nodes, 8 mm RLL hypermetabolic nodule \u2014 findings consistent with metastatic disease.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-03-30\\\",\\n      \\\"event_type\\\": \\\"Pathology\\\",\\n      \\\"brief_note\\\": \\\"Bronchoscopy with EBUS-guided FNA confirming metastatic non-small cell carcinoma, favor adenocarcinoma; supports stage IV diagnosis.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-04-30\\\",\\n      \\\"event_type\\\": \\\"Clinical/Plan\\\",\\n      \\\"brief_note\\\": \\\"Chemotherapy education completed; plan to begin carboplatin + paclitaxel with pembrolizumab integration.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-06-10\\\",\\n      \\\"event_type\\\": \\\"Treatment\\\",\\n      \\\"brief_note\\\": \\\"First documented combined administration: carboplatin 550 mg IV, paclitaxel 300 mg IV, pembrolizumab 200 mg IV.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-08-04\\\",\\n      \\\"event_type\\\": \\\"Imaging\\\",\\n      \\\"brief_note\\\": \\\"Restaging PET/CT: partial response with decreased size and metabolic activity of primary lesion and mediastinal/hilar nodes.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-08-10\\\",\\n      \\\"event_type\\\": \\\"Molecular testing\\\",\\n      \\\"brief_note\\\": \\\"NGS: KRAS p.G12C mutation identified; PD-L1 reported negative.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-08-11\\\",\\n      \\\"event_type\\\": \\\"Lab/Endocrine\\\",\\n      \\\"brief_note\\\": \\\"Severe hypothyroidism (TSH 159) detected; levothyroxine 25 mcg started.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-09-24\\\",\\n      \\\"event_type\\\": \\\"Treatment\\\",\\n      \\\"brief_note\\\": \\\"Completed 6 cycles of carboplatin + paclitaxel + pembrolizumab.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-10-22\\\",\\n      \\\"event_type\\\": \\\"Imaging\\\",\\n      \\\"brief_note\\\": \\\"Follow-up PET: continued response with reduced size and SUV of lingular nodule (e.g., 27 x 22 mm, SUV 6.9).\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2020-12-28\\\",\\n      \\\"event_type\\\": \\\"Treatment\\\",\\n      \\\"brief_note\\\": \\\"Initiation of maintenance pembrolizumab (200 mg).\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2021-02-15\\\",\\n      \\\"event_type\\\": \\\"Imaging\\\",\\n      \\\"brief_note\\\": \\\"CT chest: interval increase of lingular mass (3.6 x 2.5 cm vs prior 2.7 x 2.4 cm); LLL nodule enlarged to 10 x 4 mm.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2021-03-11\\\",\\n      \\\"event_type\\\": \\\"Procedure\\\",\\n      \\\"brief_note\\\": \\\"EGD with balloon dilation (15 mm) for Schatzki-type GE-junction stricture; gastric/duodenal biopsies negative.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2021-03-22\\\",\\n      \\\"event_type\\\": \\\"Imaging\\\",\\n      \\\"brief_note\\\": \\\"PET/CT: interval metabolic progression with intensely FDG-avid 4.1 cm left lung mass and new/increased left hilar/infrahilar nodes.\\\"\\n    },\\n    {\\n      \\\"date\\\": \\\"2021-03-27\\\",\\n      \\\"event_type\\\": \\\"Clinical/Plan\\\",\\n      \\\"brief_note\\\": \\\"Plan documented to discontinue pembrolizumab and consider KRAS-directed therapy (adagrasib) with referral for second opinion; follow-up labs and clinic visits scheduled.\\\"\\n    }\\n  ],\\n  \\\"history_summary\\\": \\\"59-year-old female diagnosed with stage IVA (T4 N3 M1a) NSCLC, adenocarcinoma, initially staged by PET/CT (Mar 2020) with mediastinal nodal involvement and metastatic nodules. Pathology confirmed metastatic adenocarcinoma (EBUS 2020-03-30). She received induction carboplatin + paclitaxel with pembrolizumab (6 cycles completed 2020-09-24) followed by maintenance pembrolizumab; NGS revealed a KRAS p.G12C mutation and PD-L1 was negative. After an initial partial response, interval growth on CT and metabolic progression on PET/CT (Mar 2021) prompted documented plans to discontinue pembrolizumab and pursue KRAS-directed therapy (adagrasib) pending second opinion.\\\",\\n  \\\"error_message\\\": null\\n}\\n\\nback to you: Orchestrator\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    },\n    {\n      \"ai_model_id\": \"gpt-5-mini\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-CBdncEZzjckycqCTfOSMUhhbHxE2j\",\n        \"created\": 1756890632,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 33086,\n          \"completion_tokens\": 813\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"Orchestrator\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"PatientStatus, please proceed.\\n\\nPlanned task for you:\\n- Produce the patient's current status using the PatientHistory output. Deliver a concise structured summary containing:\\n  - age\\n  - stage at diagnosis (AJCC staging as documented)\\n  - primary site (anatomic)\\n  - histology\\n  - biomarkers (list with results)\\n  - treatment history (key systemic therapies, dates/cycles)\\n  - ECOG performance status (as recorded)\\n  - current clinical status (one-sentence latest assessment, e.g., progression vs response, based on most recent imaging)\\n\\nData available from PatientHistory (use these values unless you need clarification):\\n- Age: 59 years\\n- Stage at diagnosis: T4 N3 M1a (IVA)\\n- Primary site: Left lung \u2014 lingular mass\\n- Histology: Adenocarcinoma (NSCLC)\\n- Biomarkers: KRAS p.G12C positive; PD-L1 negative\\n- Treatment history: Induction carboplatin + paclitaxel + pembrolizumab (6 cycles completed 2020-09-24); maintenance pembrolizumab started 2020-12-28; plan documented 2021-03-27 to discontinue pembrolizumab and consider KRAS-directed therapy (adagrasib)\\n- ECOG: 1 (documented during chemo education)\\n\\nQuestions for you before composing the status:\\n- Do you require any additional numerical values or dates from PatientHistory (e.g., exact dosing dates/doses beyond what\u2019s listed), or is the above sufficient?\\n- Please confirm the output format you will use (concise paragraph plus structured bullet list is fine).\\n\\nDeliverable:\\n- A concise current-status summary (2\u20134 short bullets/1 paragraph) suitable for inclusion in the tumor board Word report.\\n- Please conclude your response with: back to you: Orchestrator\\n\\nUser, quick check:\\n- User, do you want ECOG or baseline labs (e.g., CEA) included in the patient status section if available? If yes, confirm now.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    }\n  ]\n}",
  "patient_id": "patient_4",
  "patient_data": [
    {
      "id": "0ab80fbd-9c7a-4bce-abd8-1ba44c86ec94",
      "type": "clinical note"
    },
    {
      "id": "31bbcfb4-704e-4e28-8f33-f0db97d5598d",
      "type": "clinical note"
    },
    {
      "id": "39c1c467-6e6a-4e2f-b82e-b70750cbd933",
      "type": "clinical note"
    },
    {
      "id": "47b10e30-fc09-4438-a2c8-44741aac610f",
      "type": "clinical note"
    },
    {
      "id": "4a16150f-c95e-47cd-81a4-78511581d635",
      "type": "clinical note"
    },
    {
      "id": "5184613c-11f7-4ecb-985a-1920daba51c1",
      "type": "clinical note"
    },
    {
      "id": "853d37db-1ee9-45d5-a888-e942235351b5",
      "type": "clinical note"
    },
    {
      "id": "86a93cdb-da8b-4c9a-b07c-641a19fb5ed9",
      "type": "clinical note"
    },
    {
      "id": "91ad6865-6998-4f5b-89f0-3efc4d641c9c",
      "type": "clinical note"
    },
    {
      "id": "97e2279b-a283-46b2-a246-9c061b163b0b",
      "type": "clinical note"
    },
    {
      "id": "99b1079d-3420-4197-ac7d-708c97203f2e",
      "type": "clinical note"
    },
    {
      "id": "a550f679-3604-4bdc-9308-573329d886d1",
      "type": "clinical note"
    },
    {
      "id": "a73bad38-58eb-48ea-8104-8692fc6c6096",
      "type": "clinical note"
    },
    {
      "id": "b41550bb-2fd8-4963-9443-92a2429d4dbb",
      "type": "clinical note"
    },
    {
      "id": "cc7a9b1c-6bfe-49c2-9255-85022eda4dbc",
      "type": "clinical note"
    },
    {
      "id": "f051320d-2f94-4daa-a819-05c8eff11b3f",
      "type": "clinical note"
    },
    {
      "filename": "x-ray.png",
      "type": "x-ray image",
      "url": "https://stapphaolmatevx.blob.core.windows.net/patient-data/patient_4/images/x-ray.png"
    }
  ],
  "display_blob_urls": [],
  "display_clinical_trials": [],
  "output_data": [],
  "healthcare_agents": {}
}